Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 May;25(3):266-273.e5.
doi: 10.1016/j.cllc.2024.03.003. Epub 2024 Mar 15.

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Edward B Garon  1 , Byoung Chul Cho  2 , Alexander Luft  3 , Jorge Alatorre-Alexander  4 , Sarayut Lucien Geater  5 , Dmytro Trukhin  6 , Sang-We Kim  7 , Grygorii Ursol  8 , Maen Hussein  9 , Farah Louise Lim  10 , Cheng-Ta Yang  11 , Luiz Henrique Araujo  12 , Haruhiro Saito  13 , Niels Reinmuth  14 , Milena Kohlmann  15 , Caitlin Lowery  15 , Helen Mann  16 , Solange Peters  17 , Tony S Mok  18 , Melissa L Johnson  19
Affiliations
Free article
Clinical Trial

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Edward B Garon et al. Clin Lung Cancer. 2024 May.
Free article
No abstract available

Keywords: Clinical trial; Cytotoxic T-lymphocyte-associated antigen 4; Immune checkpoint inhibitor; Immunotherapy; Programmed cell death ligand-1.

PubMed Disclaimer

Publication types

MeSH terms